ASH Clinical News Focus on Myeloma | Page 6

OCTOBER 2015 AMERICAN SOCIETY OF HEMATOLOGY HEADQUARTERS 2021 L Street NW, Suite 900 Washington, DC 20036 www.hematology.org Tel: [phone] EDITOR-IN-CHIEF Mikkael Sekeres, MD, MS Vice-Chair for Clinical Research Director, Leukemia Program Cleveland Clinic, Taussig Cancer Institute Cleveland, OH ASSOCIATE EDITORS Beth Faiman, CNP, PhD Cleveland Clinic Cleveland, OH Alice Ma, MD University of North Carolina School of Medicine Chapel Hill, NC CONTENTS David Steensma, MD Dana-Farber Cancer Institute Boston, MA Keith Stewart, MBChB, MBA Mayo Clinic Scottsdale, AZ FEATURES 6 PUBLISHER American Medical Communications EDITORIAL MANAGING EDITORS Ariel Jones-DeMaio, AMC Karen Learner, ASH ART DIRECTOR Ari Mihos ASSISTANT ART DIRECTOR Charlene DePrizio DIGITAL PROJECTS MANAGER Chris Gedikli ADVERTISING ACCOUNT MANAGER Nick Luciano [email protected] Gene Conselyea [email protected] Recruitment advertising orders can be sent to: DIRECTOR, RECRUITMENT CLASSIFIEDS Lauren Morgan [email protected] ©2015 by the American Society of Hematology. All materials contained in this newsletter are protected by copyright laws and may not be used, reproduced, or otherwise exploited in any manner without the express prior written permission of ASH Clinical News. Any third-party materials communicated to ASH Clinical News become its copyrighted property and may be used, reproduced, or otherwise exploited by ASH Clinical News. 7 In the Pipeline 9 Meeting News Recently approved agents and agents currently under investigation for the treatment of multiple myeloma 9 Safety Profile of Daratumumab in Relapsed/Refractory Multiple Myeloma Patients Clinical Trial Updates 10 Researchers Identify Markers of Relapse in Post-Transplant Multiple Myeloma Patients A look at the ongoing clinical trials in multiple myeloma 10 Pinpointing the Mechanisms that Transform MGUS into Myeloma 11 Safety and Tolerability of MOR202 in Relapsed/Refractory Myeloma Patients 12 IMWG Revises International Staging System for Multiple Myeloma 12 Adding Elotuzumab to Standard Therapy Reduces Progression Risk for Multiple Myeloma Patients 13 ENDEAVOR: Carfilzomib Bests Bortezomib in Relapsed Multiple Myeloma All correspondence for the American Society of Hematology should be sent to: American Society of Hematology, 2021 L Street NW, Suite 900, Washington DC 20036. Neither the American Society of Hematology nor the publisher is responsible for statements made by any contributor. Statements or opinions expressed in ASH Clinical News magazine do not represent official policy of the American Society of Hematology unless so stated. No responsibility is assumed by the American Society of Hematology or the Publisher for any injury or damage to persons or property as a matter of product  liability, negligence or otherwise or from any use or operation of any methods, products, instructions or ideas contained in the material herein.  Although all advertising material published in ASH Clinical News magazine is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement by the American Society of Hematology or the Publisher of the quality or value of such product or of the claim made